True North Advisors LLC Cuts Stake in AbbVie Inc. $ABBV

True North Advisors LLC lessened its stake in AbbVie Inc. (NYSE:ABBV) by 15.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,735 shares of the company’s stock after selling 2,892 shares during the quarter. True North Advisors LLC’s holdings in AbbVie were worth $3,959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ABBV. Ranch Capital Advisors Inc. raised its stake in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after buying an additional 4,017 shares during the last quarter. Calamos Advisors LLC boosted its stake in shares of AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock worth $106,543,000 after buying an additional 15,458 shares during the last quarter. Wedge Capital Management L L P NC boosted its stake in shares of AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after buying an additional 9,380 shares during the last quarter. Axecap Investments LLC grew its holdings in shares of AbbVie by 713.2% in the fourth quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock worth $3,729,000 after acquiring an additional 14,313 shares during the period. Finally, Legacy Edge Advisors LLC bought a new stake in shares of AbbVie in the fourth quarter worth $1,265,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.1%

Shares of NYSE:ABBV opened at $249.20 on Monday. The stock has a 50 day moving average of $244.94 and a 200 day moving average of $226.16. The company has a market cap of $440.29 billion, a PE ratio of 70.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the business earned $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

Analysts Set New Price Targets

A number of research analysts have weighed in on ABBV shares. HSBC reissued a “buy” rating and issued a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Barclays increased their price objective on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Evercore set a $235.00 price objective on shares of AbbVie in a report on Friday, May 15th. Guggenheim boosted their target price on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.50.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.